Amgens AMG-162 for treatment of osteoporosis will become a blockbuster by 2013 Decision Resources.

Amgen’s AMG-162 for treatment of osteoporosis will become a blockbuster by 2013 Decision Resources, Inc., forecasts that Amgen’s novel biological agent for the treatment of osteoporosis, AMG-162, can be a blockbuster by 2013 sildenafil citrate 100mg click here . Premium pricing of AMG-162 will propel the product sales of this agent. The new Pharmacor study entitled Osteoporosis also discovers that the total osteoporosis marketplace – – including osteopenia – – increase at a 4.6 percent annual rate. Factors that may drive the market’s growth include substantial boosts in the drug-treated patient population and the release of new agents that want less-frequent administration and offer novel mechanisms of action.

click here

When the scores from the Amorfix check were correlated with scores from the MMSE , the results demonstrated that aggregates were not only within cerebrospinal liquid from late-stage AD, but also in sufferers with early stage AD or moderate cognitive impairment . In addition, the data claim that the Amorfix check is superior for identification of patients with MCI in comparison with the measurements of monomeric Abeta 1-42 alone. Related StoriesProtein sensor for proprioception foundPresence of connexin proteins suppresses primary tumor growthRice researchers solve long-position mystery about hemophilia protein This accomplishment represents a significant step forward for our Alzheimer’s disease diagnostic plan , said Dr.

Other Posts From Category "immunology":

Related Posts